{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:56:41Z","timestamp":1792652201625,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajogmfm.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics & Gynecology MFM"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ajogmf.2023.101108","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T09:56:22Z","timestamp":1690710982000},"page":"101108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2465-6747","authenticated-orcid":false,"given":"Tracy A.","family":"Manuck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Gyamfi-Bannerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Saade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajogmf.2023.101108_bib0001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2006-2386","article-title":"Cost of hospitalization for preterm and low birth weight infants in the United States","volume":"120","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2016.01.004","article-title":"Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort","volume":"215","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0003","doi-asserted-by":"crossref","first-page":"426.e1","DOI":"10.1016\/j.ajog.2014.01.046","article-title":"Correlation between initial neonatal and early childhood outcomes following preterm birth","volume":"210","author":"Manuck","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0035-1571150","article-title":"Short- and long-term outcomes of moderate and late preterm infants","volume":"33","author":"Natarajan","year":"2016","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0005","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1542\/peds.2007-2976","article-title":"Impact of intensive care practices on short-term and long-term outcomes for extremely preterm infants: comparison between the British Isles and France","volume":"122","author":"Bodeau-Livinec","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0006","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.clp.2013.07.006","article-title":"Long-term outcomes of moderately preterm, late preterm, and early term infants","volume":"40","author":"Vohr","year":"2013","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0007","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.283.12.1591","article-title":"Rates of and factors associated with recurrence of preterm delivery","volume":"283","author":"Adams","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0008","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ajog.2006.05.022","article-title":"Recurrence of spontaneous versus medically indicated preterm birth","volume":"195","author":"Ananth","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004947.pub3","article-title":"Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth","author":"Dodd","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajog.2013.04.027","article-title":"Progesterone is not the same as 17\u03b1-hydroxyprogesterone caproate: implications for obstetrical practice","volume":"208","author":"Romero","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1471-0528.1990.tb01740.x","article-title":"Progestogen administration in pregnancy may prevent preterm delivery","volume":"97","author":"Keirse","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0012","series-title":"Analytic profiles of drug substances","author":"caproate","year":"1975"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0013","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1749-6632.1997.tb48549.x","article-title":"Vaginal drug delivery: the first uterine pass effect","volume":"828","author":"Bulletti","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0014","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1997.tb48550.x","article-title":"The first uterine pass effect","volume":"828","author":"De Ziegler","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/09513599609023607","article-title":"Further data favoring the hypothesis of the uterine first-pass effect of vaginally administered micronized progesterone","volume":"10","author":"Balasch","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0016","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0017","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/AOG.0000000000003991","article-title":"Re-examining the Meis trial for evidence of false-positive results","volume":"136","author":"Sibai","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0018","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.ajog.2017.01.022","article-title":"Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth","volume":"216","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0019","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2012.03.010","article-title":"Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice","volume":"206","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/AOG.0b013e3182723b1b","article-title":"The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth","volume":"120","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0021","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0039-3400227","article-title":"17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial","volume":"37","author":"Blackwell","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajog.2014.12.011","article-title":"Why the United States preterm birth rate is declining","volume":"213","author":"Schoen","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0140-6736(12)61856-X","article-title":"Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index","volume":"381","author":"Chang","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0024","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-0029-1215432","article-title":"Attitudes and practices regarding use of progesterone to prevent preterm births","volume":"26","author":"Henderson","year":"2009","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.AOG.0000275287.08520.4a","article-title":"Prediction and prevention of recurrent spontaneous preterm birth","volume":"110","author":"Spong","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0026","first-page":"125","article-title":"Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques: evidence for functional progesterone withdrawal at parturition","volume":"9","author":"Haluska","year":"2002","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0027","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ajog.2005.05.071","article-title":"Progesterone receptor isoform (A\/B) ratio of human fetal membranes increases during term parturition","volume":"193","author":"Oh","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0028","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/1933719115589414","article-title":"Progesterone metabolites produced by cytochrome P450 3A modulate uterine contractility in a murine model","volume":"22","author":"Patil","year":"2015","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0029","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.ajog.2008.06.085","article-title":"Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions","volume":"199","author":"Ruddock","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1477-7827-2-80","article-title":"Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro","volume":"2","author":"Sexton","year":"2004","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0031","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/1933719109340926","article-title":"The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy","volume":"16","author":"Anderson","year":"2009","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0032","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.ajog.2013.01.020","article-title":"Prevention of preterm birth by progestational agents: what are the molecular mechanisms?","volume":"208","author":"Nold","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0033","doi-asserted-by":"crossref","first-page":"396.e1","DOI":"10.1016\/j.ajog.2012.08.001","article-title":"Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation","volume":"207","author":"Caritis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0034","doi-asserted-by":"crossref","first-page":"158.e1","DOI":"10.1016\/j.ajog.2014.02.018","article-title":"Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy","volume":"211","author":"Amaral","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0035","doi-asserted-by":"crossref","first-page":"561.e1","DOI":"10.1016\/j.ajog.2010.07.016","article-title":"Intramuscular 17\u03b1-hydroxyprogesterone caproate administration attenuates immunoresponsiveness of maternal peripheral blood mononuclear cells","volume":"203","author":"Foglia","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0036","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1515\/JPM.2005.089","article-title":"Hydroxyprogesterone caproate and progesterone increase tumor necrosis factor-alpha production in lipopolysaccharide stimulated whole blood from non-pregnant women","volume":"33","author":"Amory","year":"2005","journal-title":"J Perinat Med"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0037","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/1933719110363618","article-title":"Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth","volume":"17","author":"Luo","year":"2010","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0038","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajog.2006.06.013","article-title":"The use of progestational agents for preterm birth: lessons from a mouse model","volume":"195","author":"Elovitz","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.08.010","article-title":"Vaginal progesterone, but not 17\u03b1-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface","volume":"213","author":"Furcron","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0040","doi-asserted-by":"crossref","first-page":"119.e1","DOI":"10.1016\/j.ajog.2007.06.022","article-title":"Human decidual cell toll-like receptor signaling in response to endotoxin: the effect of progestins","volume":"198","author":"Simhan","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0041","doi-asserted-by":"crossref","first-page":"109","DOI":"10.55133\/eji.300210","article-title":"Effect of 17-hydroxyprogesterone caproate on interleukin-6 and tumor necrosis factor-alpha in expectantly managed early-onset preeclampsia","volume":"30","author":"Othman","year":"2023","journal-title":"Egypt J Immunol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209346","article-title":"Progesterone effects on vaginal cytokines in women with a history of preterm birth","volume":"13","author":"Garry","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0043","first-page":"1115","article-title":"American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Use of progesterone to reduce preterm birth","volume":"102","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0044","doi-asserted-by":"crossref","first-page":"375.e1","DOI":"10.1016\/j.ajog.2009.08.015","article-title":"Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length","volume":"201","author":"Owen","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0045","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1056\/NEJMp2031055","article-title":"Withdrawing approval of Makena - a proposal from the FDA Center for Drug Evaluation and Research","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0046","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(21)00217-8","article-title":"Evaluating Progestogens for Preventing preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0047","doi-asserted-by":"crossref","first-page":"410.e1","DOI":"10.1016\/j.ajog.2009.07.009","article-title":"The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time","volume":"201","author":"Durnwald","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0048","doi-asserted-by":"crossref","first-page":"269.e1","DOI":"10.1016\/j.ajog.2013.05.027","article-title":"The effect of intramuscular progesterone on the rate of cervical shortening","volume":"209","author":"Pessel","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0049","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.ajog.2012.09.013","article-title":"17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm","volume":"207","author":"Grobman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jama.2015.10244","article-title":"Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012","volume":"314","author":"Stoll","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0051","first-page":"379","article-title":"Recurrence of preterm birth in singleton and twin pregnancies","volume":"98","author":"Bloom","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0052","first-page":"1","article-title":"Highlights of trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-96","volume":"47","author":"Ventura","year":"1999","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0053","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/0002-9378(79)90742-7","article-title":"The tendency to repeat gestational age and birth weight in successive births","volume":"135","author":"Bakketeig","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0054","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/0029-7844(95)00275-V","article-title":"Implications of idiopathic preterm delivery for previous and subsequent pregnancies","volume":"86","author":"Kristensen","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajog.2015.12.002","article-title":"17 alpha-hydroxyprogesterone caproate for preterm prevention: issues in subgroup analysis","volume":"214","author":"Klebanoff","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0056","doi-asserted-by":"crossref","first-page":"376.e1","DOI":"10.1016\/j.ajog.2015.12.010","article-title":"Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth","volume":"214","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0057","doi-asserted-by":"crossref","first-page":"622.e1","DOI":"10.1016\/j.ajog.2016.07.013","article-title":"Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system","volume":"215","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0058","article-title":"Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention","volume":"210","author":"Manuck","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0059","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/aogs.13027","article-title":"Recurrence of second trimester miscarriage and extreme preterm delivery at 16-27 weeks of gestation with a focus on cervical insufficiency and prophylactic cerclage","volume":"95","author":"Sneider","year":"2016","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0060","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ajog.2005.05.040","article-title":"Periviable birth at 20 to 26 weeks of gestation: proximate causes, previous obstetric history and recurrence risk","volume":"193","author":"Mercer","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0061","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajog.2010.02.004","article-title":"Care for women with prior preterm birth","volume":"203","author":"Iams","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0062","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajog.2011.10.864","article-title":"Challenges in defining and classifying the preterm birth syndrome","volume":"206","author":"Kramer","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0063","first-page":"444","article-title":"Pregnancy outcome following a second-trimester loss","volume":"81","author":"Goldenberg","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0064","doi-asserted-by":"crossref","first-page":"844.e1","DOI":"10.1016\/j.ajog.2015.08.014","article-title":"Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?","volume":"213","author":"Heyborne","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0065","doi-asserted-by":"crossref","first-page":"233.e1","DOI":"10.1016\/j.ajog.2015.04.018","article-title":"Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate","volume":"213","author":"Co","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0066","doi-asserted-by":"crossref","first-page":"257.e1","DOI":"10.1016\/j.ajog.2010.06.020","article-title":"Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice","volume":"203","author":"Gonz\u00e1lez-Quintero","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0067","doi-asserted-by":"crossref","first-page":"275.e1","DOI":"10.1016\/j.ajog.2011.06.043","article-title":"Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery","volume":"205","author":"Gonzalez-Quintero","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0068","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3109\/14767058.2011.614657","article-title":"Recurrent preterm birth in women treated with 17 \u03b1-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy","volume":"25","author":"Coleman","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0069","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.ajog.2010.02.019","article-title":"17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length","volume":"202","author":"Berghella","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0070","doi-asserted-by":"crossref","first-page":"371.e1","DOI":"10.1016\/j.ajog.2017.05.022","article-title":"Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth","volume":"217","author":"Ning","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0071","doi-asserted-by":"crossref","first-page":"40.e1","DOI":"10.1016\/j.ajog.2011.03.028","article-title":"Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation","volume":"205","author":"Caritis","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0072","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.ajog.2012.08.015","article-title":"Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation","volume":"207","author":"Caritis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0073","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.12990","article-title":"Population pharmacokinetics of 17\u03b1-hydroxyprogesterone caproate in singleton gestation","volume":"82","author":"Sharma","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0074","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1124\/dmd.115.064998","article-title":"Variability in expression of CYP3A5 in human fetal liver","volume":"43","author":"Vyhlidal","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0076","doi-asserted-by":"crossref","first-page":"128.e1","DOI":"10.1016\/j.ajog.2013.10.008","article-title":"Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth","volume":"210","author":"Caritis","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0077","doi-asserted-by":"crossref","first-page":"369.e1","DOI":"10.1016\/j.ajog.2017.05.019","article-title":"The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth","volume":"217","author":"Bustos","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0078","article-title":"Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery","volume":"5","author":"Caritis","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0079","doi-asserted-by":"crossref","first-page":"194.e1","DOI":"10.1016\/j.ajog.2013.01.032","article-title":"Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial","volume":"208","author":"Senat","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0080","doi-asserted-by":"crossref","first-page":"135.e1","DOI":"10.1016\/j.ajog.2011.03.048","article-title":"Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate","volume":"205","author":"Manuck","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0081","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/1471-0528.14485","article-title":"Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study","volume":"125","author":"Manuck","year":"2018","journal-title":"BJOG"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0082","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0037-1613682","article-title":"Epigenetic regulation of the nitric oxide pathway, 17-\u03b1 hydroxyprogesterone caproate, and recurrent preterm birth","volume":"35","author":"Manuck","year":"2018","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0083","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/epi-2020-0346","article-title":"Mid-pregnancy maternal blood nitric oxide-related gene and miRNA expression are associated with preterm birth","volume":"13","author":"Manuck","year":"2021","journal-title":"Epigenomics"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0084","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1213\/ANE.0000000000000708","article-title":"The effect of progestins on tumor necrosis factor \u03b1-induced matrix metalloproteinase-9 activity and gene expression in human primary amnion and chorion cells in vitro","volume":"120","author":"Allen","year":"2015","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/1471-0528.13744","article-title":"Pharmacogenomics of preterm birth prevention and treatment","volume":"123","author":"Manuck","year":"2016","journal-title":"BJOG"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0086","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/AOG.0b013e3181d53b83","article-title":"Progesterone receptor genotype, family history, and spontaneous preterm birth","volume":"115","author":"Manuck","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0087","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1043-2760(03)00003-1","article-title":"Progesterone in gestational diabetes mellitus: guilty or not guilty?","volume":"14","author":"Br\u0103ni\u015fteanu","year":"2003","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0088","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/563243","article-title":"Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate","volume":"2014","author":"Egerman","year":"2014","journal-title":"J Obes"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0089","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.ajog.2017.02.025","article-title":"17-alpha hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study","volume":"216","author":"Nelson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0090","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/01.AOG.0000281348.51499.bc","article-title":"Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo","volume":"110","author":"Northen","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0091","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ajog.2021.10.035","article-title":"In utero exposure to 17\u03b1-hydroxyprogesterone caproate and risk of cancer in offspring","volume":"226","author":"Murphy","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101108_bib0092","unstructured":"Betamethasone sodium phosphate and betamethasone acetate. Available at:https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/be3e57df-339a-4b7c-9528-d478af8c7855\/spl-doc?hl=betamethasone. Accessed June 1, 2023."}],"container-title":["American Journal of Obstetrics & Gynecology MFM"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933323002501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933323002501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:54:32Z","timestamp":1762905272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589933323002501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2589933323002501"],"URL":"https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101108","relation":{},"ISSN":["2589-9333"],"issn-type":[{"value":"2589-9333","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics & Gynecology MFM","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101108"}}